Pancreatic cancer, or cancer of the pancreas, is one of the more dangerous forms of cancer.Diabetes is listed as a risk factor and also a potential consequence of pancreatic cancer.
The pancreas is an organ that sits close behind the stomach and plays an important part in digestion as well as in keeping our blood sugar levels at safe levels.
Pancreatic cancer is when cells start being produced in the pancreas in an uncontrolled fashion by the body. This can lead to a number of health risks which can include diabetes in some cases.
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
H8804 |
Avotaciclib |
1983983-41-0 | Avotaciclib is a novel cyclin-dependent kinase inhibitor,exhibited inhibitory activities against CDK1/cyclinB, CDK2/cyclinE, CDK4/cyclinD, CDK5/p25 and CDK6/cyclinD with IC50 values of 1.5 nM , 1.5 nM, 854.5 nM, 2.4 nM and >220 nM, resp. |
H8346 |
MRK-003 |
623165-93-5 | A potent γ-secretase inhibitor with IC50 of 0.4 nM, inhibition of Aβ secretion from SH-SY5Y SPA4CT cells; inhibits the γ-secretase-mediated cleavage of the Notch receptor, reduces tumor cell proliferation, inhibits serum independence, and induces apoptosis in vitro and in vivo using mouse xenograft models. |
H8305 |
Saridegib |
1037210-93-7 |
Saridegib (Patidegib, IPI-926) is a potent and orally active Hedgehog (Hh) pathway antagonist with IC50 of 7 nM; binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO; demonstrates improved pharmaceutical properties and potency and a favorable pharmacokinetic profile relative to cyclopamine and IPI-269609; completely suppresses tumor growth in a Hh-dependent medulloblastoma allograft model. |
H7916 |
GSK-2256098 |
1224887-10-8 |
GSK-2256098 (GTPL-7939) is a potent, selective, reversible and ATP-competitive inhibitor of FAK kinase with Ki of 0.4 nM; dispalys high selectivity over a panel of 261 kinases, including the nearest FAK family member, Pyk2 (>1,000-fold); inhibits FAK activity through targeting the phosphorylation site of FAK Y397; decreases levels of phosphorylated Akt and ERK, cell viability, anchorage-independent growth, and motility in L3.6P1 cells; causes lower microvessel density, less cellular proliferation, and higher apoptosis rates in the Ishikawa model. |
H7229 |
NVP-AUY922 |
747412-49-3 | A potent and selective HSP90 inhibitor with IC50 of 21 and 7.8 nM for HSP90β and HSP90α, respectively; weakly inhibits HSP90 family members GRP94 and TRAP-1 (Ki=108 and 53 nM), shows no inhibition of HSP72 ATPase and little or no activity against a range of 13 kinases; inhibits proliferation of human tumor cells (GI50=2-40 nM), induces G(1)-G(2) arrest and apoptosis; exhibits in vivo activity against xenograft tumor growth, angiogenesis and metastasis. |
H5641 |
Triptolide |
38748-32-2 | The active diterpene in the traditional Chinese medicine Lei Gong Teng, induces Ca(2+) release by a polycystin-2 (PC2)-dependent mechanism; arrests cellular proliferation and attenuates overall cyst formation by restoring Ca(2+) signaling in a murine model of ADPKD; also covalently binds to human XPB (ERCC3), a subunit of the transcription factor TFIIH, and inhibits its DNA-dependent ATPase activity, which leads to the inhibition of RNA polymerase II-mediated transcription; inhibits TAK1 kinase activity by interfering with the formation of the TAK1-TAB1 complex in macrophages. |
H5637 |
Minnelide |
1254702-87-8 | A water-soluble prodrug of triptolide that is highly effective in reducing pancreatic tumor growth and spread, and improving survival; efficiently downregulates both CD133(-) and CD133(+) population in the tumors, resulting in a 60% decrease in tumor volume; also is very effective as a therapeutic option against Castration Resistant Prostate Cancer (CRPC). |
H5239 |
GNE-140 racemate |
1802977-61-2 |
The racemate of GNE-140, a novel potent, selective lactate dehydrogenase (LDH) inhibitor with IC50 of 3, 5, and 5 nM for LDHA, LDHB, and LDHC, respectively; displays no inhibition on malate MDH-1, MDH-2 (IC50>10 uM for both enzymes), and no appreciable inhibition against a panel of 301 kinases (<50% inhibition at 1 uM); perturbs glycolysis and inhibits proliferation in MIA PaCa-2 cells (IC50=0.43 uM), decreases glucose uptake (IC50=0.47 uM); pancreatic cell lines that utilize oxidative OXPHOS rather than glycolysis are inherently resistant to GNE-140, which can be resensitized to GNE-140 with the OXPHOS inhibitor phenformin. |
H5236 |
(R)-GNE-140 |
2003234-63-5 |
(R)-GNE-140 (GNE-140)?is a novel potent, selective lactate dehydrogenase (LDH) inhibitor with IC50 of 3, 5, and 5 nM for LDHA, LDHB, and LDHC, respectively; displays no inhibition on malate MDH-1, MDH-2 (IC50>10 uM for both enzymes), and no appreciable inhibition against a panel of 301 kinases (<50% inhibition at 1 uM); perturbs glycolysis and inhibits proliferation in MIA PaCa-2 cells (IC50=0.43 uM), decreases glucose uptake (IC50=0.47 uM); pancreatic cell lines that utilize oxidative OXPHOS rather than glycolysis are inherently resistant to GNE-140, which can be resensitized to GNE-140 with the OXPHOS inhibitor phenformin. |
H5013 |
SLC-0111 |
178606-66-1 |
SLC-0111 is a sulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor with IC50 of 45 nM and 4.5 nM for tumor-associated enzymes hCA IX and hCA XII; showed selective CA IX/XII inhibitory profiles, displays >20-fold and >100-fold selectivity over hCA II and hCA I, respectively; reduces tumor cell growth and increases apoptotic cell death in prostate cancer cells. |
086-18516630705
sales@hmobio.com
1/F, building 4, No. 358-368, Kefu Road, Jiading District, Shanghai, China